m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00900)
Name
FLUORESCEIN
Synonyms
Ful-Glo; Fluoreseptic; 41935-48-2; NSC5070
    Click to Show/Hide
Status
Approved
Structure
Formula
C20H12O5
InChI
1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H
InChIKey
GNBHRKFJIUUOQI-UHFFFAOYSA-N
PubChem CID
16850
TTD Drug ID
D06TJJ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Mothers against decapentaplegic homolog 3 (SMAD3)
ETS-related transcription factor Elf-3 (ELF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for FLUORESCEIN. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of FLUORESCEIN through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for FLUORESCEIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FLUORESCEIN through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [2], [3]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for FLUORESCEIN. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of FLUORESCEIN through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [2], [4]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for FLUORESCEIN. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of FLUORESCEIN through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [2], [5]
References
Ref 1 Involvement of Elf3 on Smad3 activation-dependent injuries in podocytes and excretion of urinary exosome in diabetic nephropathy. PLoS One. 2019 May 31;14(5):e0216788. doi: 10.1371/journal.pone.0216788. eCollection 2019.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2824).
Ref 3 N6-methyladenosine-induced circ1662 promotes metastasis of colorectal cancer by accelerating YAP1 nuclear localization. Theranostics. 2021 Feb 25;11(9):4298-4315. doi: 10.7150/thno.51342. eCollection 2021.
Ref 4 RNA demethylase ALKBH5 inhibits TGF-Beta-induced EMT by regulating TGF-Beta/SMAD signaling in non-small cell lung?cancer. FASEB J. 2022 May;36(5):e22283. doi: 10.1096/fj.202200005RR.
Ref 5 YTHDF2 Inhibits the Migration and Invasion of Lung Adenocarcinoma by Negatively Regulating the FAM83D-TGFBeta1-SMAD2/3 Pathway. Front Oncol. 2022 Feb 2;12:763341. doi: 10.3389/fonc.2022.763341. eCollection 2022.